Published in Genome Res on June 20, 2013
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet (2015) 2.17
Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma. Nat Genet (2015) 1.89
Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. Curr Opin Genet Dev (2013) 1.62
Rapid detection of structural variation in a human genome using nanochannel-based genome mapping technology. Gigascience (2014) 1.36
Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol (2015) 1.33
Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol (2013) 1.22
Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci U S A (2015) 1.18
MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches. Cell Death Differ (2014) 1.17
TET proteins and the control of cytosine demethylation in cancer. Genome Med (2015) 1.13
The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br J Cancer (2015) 1.03
SWI/SNF chromatin remodeling complexes and cancer. Am J Med Genet C Semin Med Genet (2014) 1.03
Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene (2015) 1.03
Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat Genet (2016) 1.02
Diagnosis and treatment of hepatocellular carcinoma: An update. World J Hepatol (2015) 1.02
Transcriptome profiling of archived sectioned formalin-fixed paraffin-embedded (AS-FFPE) tissue for disease classification. PLoS One (2014) 1.01
Diverse modes of genomic alteration in hepatocellular carcinoma. Genome Biol (2014) 0.99
Circulating tumor-derived DNA is shorter than somatic DNA in plasma. Proc Natl Acad Sci U S A (2015) 0.99
Functional and genetic deconstruction of the cellular origin in liver cancer. Nat Rev Cancer (2015) 0.92
The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy. Am J Pathol (2013) 0.89
Epigenetic signatures of alcohol abuse and hepatitis infection during human hepatocarcinogenesis. Oncotarget (2014) 0.87
Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid. Int J Cancer (2014) 0.86
Profiling of exome mutations associated with progression of HBV-related hepatocellular carcinoma. PLoS One (2014) 0.86
Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomas. Nat Commun (2015) 0.85
SAMD9L inactivation promotes cell proliferation via facilitating G1-S transition in hepatitis B virus-associated hepatocellular carcinoma. Int J Biol Sci (2014) 0.84
Genetic alterations in hepatocellular carcinoma: An update. World J Gastroenterol (2016) 0.83
Clinicopathological indices to predict hepatocellular carcinoma molecular classification. Liver Int (2015) 0.83
TALEN-mediated somatic mutagenesis in murine models of cancer. Cancer Res (2014) 0.83
Integrated analysis of mutation data from various sources identifies key genes and signaling pathways in hepatocellular carcinoma. PLoS One (2014) 0.83
Somatic mutations, viral integration and epigenetic modification in the evolution of hepatitis B virus-induced hepatocellular carcinoma. Curr Genomics (2014) 0.82
The mutational landscape of hepatocellular carcinoma. Clin Mol Hepatol (2015) 0.82
Target genes discovery through copy number alteration analysis in human hepatocellular carcinoma. World J Gastroenterol (2013) 0.81
Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes. World J Gastroenterol (2016) 0.81
NDRG1 promotes growth of hepatocellular carcinoma cells by directly interacting with GSK-3β and Nur77 to prevent β-catenin degradation. Oncotarget (2015) 0.81
Dr.VIS v2.0: an updated database of human disease-related viral integration sites in the era of high-throughput deep sequencing. Nucleic Acids Res (2014) 0.81
DNA markers in molecular diagnostics for hepatocellular carcinoma. Expert Rev Mol Diagn (2014) 0.80
The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma. Nat Commun (2017) 0.80
Integrated clinical, whole-genome, and transcriptome analysis of multisampled lethal metastatic prostate cancer. Cold Spring Harb Mol Case Stud (2016) 0.80
Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma. Oncotarget (2016) 0.80
HERC5 is a prognostic biomarker for post-liver transplant recurrent human hepatocellular carcinoma. J Transl Med (2015) 0.80
Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis? World J Gastrointest Oncol (2016) 0.80
SAAS-CNV: A Joint Segmentation Approach on Aggregated and Allele Specific Signals for the Identification of Somatic Copy Number Alterations with Next-Generation Sequencing Data. PLoS Comput Biol (2015) 0.80
Focal Adhesion Kinase: Insight into Molecular Roles and Functions in Hepatocellular Carcinoma. Int J Mol Sci (2017) 0.80
Enhanced cAMP-stimulated protein kinase A activity in human fibrolamellar hepatocellular carcinoma. Pediatr Res (2016) 0.80
Recurrently deregulated lncRNAs in hepatocellular carcinoma. Nat Commun (2017) 0.79
Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience. World J Hepatol (2015) 0.79
Radiomics and circulating tumor cells: personalized care in hepatocellular carcinoma? Diagn Interv Radiol (2015) 0.79
A novel KLF6-Rho GTPase axis regulates hepatocellular carcinoma cell migration and dissemination. Oncogene (2016) 0.79
Systemic therapy for advanced hepatocellular carcinoma: an update. J Gastrointest Oncol (2017) 0.79
Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma. Cell Cycle (2017) 0.79
Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. F1000Res (2016) 0.78
Dysfunction of IKZF1/MYC/MDIG axis contributes to liver cancer progression through regulating H3K9me3/p21 activity. Cell Death Dis (2017) 0.78
Epigenetic reader BRD4 inhibition as a therapeutic strategy to suppress E2F2-cell cycle regulation circuit in liver cancer. Oncotarget (2016) 0.78
Next-generation genomic profiling of hepatocellular adenomas: a new era of individualized patient care. Cancer Cell (2014) 0.78
Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection. Liver Cancer (2016) 0.78
Hepatocellular carcinoma. Wien Med Wochenschr (2014) 0.78
Genetic basis of hepatitis virus-associated hepatocellular carcinoma: linkage between infection, inflammation, and tumorigenesis. J Gastroenterol (2016) 0.78
Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics. Hepatol Int (2016) 0.77
Hepatitis B virus X protein promotes interleukin-7 receptor expression via NF-κB and Notch1 pathway to facilitate proliferation and migration of hepatitis B virus-related hepatoma cells. J Exp Clin Cancer Res (2016) 0.77
Analysing the mutational status of adenomatous polyposis coli (APC) gene in breast cancer. Cancer Cell Int (2016) 0.77
Progress and prospects of engineered sequence-specific DNA modulating technologies for the management of liver diseases. World J Hepatol (2015) 0.77
Promoter hypermethylation of Wnt pathway inhibitors in hepatitis C virus - induced multistep hepatocarcinogenesis. Virol J (2014) 0.77
Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib. Oncotarget (2015) 0.77
Enhancer of rudimentary homolog regulates DNA damage response in hepatocellular carcinoma. Sci Rep (2015) 0.77
DNA methylation at hepatitis B viral integrants is associated with methylation at flanking human genomic sequences. Genome Res (2015) 0.77
Copy number variation analysis based on AluScan sequences. J Clin Bioinforma (2014) 0.77
Identification of important long non-coding RNAs and highly recurrent aberrant alternative splicing events in hepatocellular carcinoma through integrative analysis of multiple RNA-Seq datasets. Mol Genet Genomics (2015) 0.76
Liver carcinogenesis: from naughty chemicals to soothing fat and the surprising role of NRF2. Carcinogenesis (2016) 0.76
Genome-wide association study identifies 8p21.3 associated with persistent hepatitis B virus infection among Chinese. Nat Commun (2016) 0.76
β-catenin mutation is correlated with a favorable prognosis in patients with hepatocellular carcinoma. Mol Clin Oncol (2015) 0.76
Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy. Oncotarget (2017) 0.75
MYC Deregulation in Primary Human Cancers. Genes (Basel) (2017) 0.75
Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral Heterogeneity. J Cancer (2016) 0.75
Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2. Cell Death Differ (2017) 0.75
Action and function of Wnt/β-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma. J Gastroenterol (2016) 0.75
Whole-genome mutational analysis: cause and effect of noncoding and structural mutations in liver cancer. Hepatobiliary Surg Nutr (2017) 0.75
A Positive TGF-β/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer. Neoplasia (2016) 0.75
Identification of the β-catenin/JNK/prothymosin-alpha axis as a novel target of sorafenib in hepatocellular carcinoma cells. Oncotarget (2015) 0.75
Gene copy number variations in the leukocyte genome of hepatocellular carcinoma patients with integrated hepatitis B virus DNA. Oncotarget (2016) 0.75
HBV DNA Integration: Molecular Mechanisms and Clinical Implications. Viruses (2017) 0.75
Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives. J Hepatocell Carcinoma (2014) 0.75
Mutation Detection in an Antibody-Producing Chinese Hamster Ovary Cell Line by Targeted RNA Sequencing. Biomed Res Int (2016) 0.75
A Hybrid Chalcone Combining the Trimethoxyphenyl and Isatinyl Groups Targets Multiple Oncogenic Proteins and Pathways in Hepatocellular Carcinoma Cells. PLoS One (2016) 0.75
Whole-exome sequencing identified mutational profiles of high-grade colon adenomas. Oncotarget (2017) 0.75
FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. J Exp Clin Cancer Res (2017) 0.75
Wnt-/-β-catenin pathway signaling in human hepatocellular carcinoma. World J Hepatol (2015) 0.75
Multi-OMICs and Genome Editing Perspectives on Liver Cancer Signaling Networks. Biomed Res Int (2016) 0.75
The importance of a multidisciplinary approach to hepatocellular carcinoma. J Multidiscip Healthc (2017) 0.75
Transposon mouse models to elucidate the genetic mechanisms of hepatitis B viral induced hepatocellular carcinoma. World J Gastroenterol (2015) 0.75
Exome Sequencing of Oral Squamous Cell Carcinoma Reveals Molecular Subgroups and Novel Therapeutic Opportunities. Theranostics (2017) 0.75
Genomic and Epigenomic Heterogeneity of Hepatocellular Carcinoma. Cancer Res (2017) 0.75
Molecular Pathogenesis of Hepatocellular Carcinoma. Liver Cancer (2016) 0.75
Liver cancer oncogenomics: opportunities and dilemmas for clinical applications. Hepat Oncol (2015) 0.75
Current Proceedings in the Molecular Dissection of Hepatocellular Adenomas: Review and Hands-on Guide for Diagnosis. Int J Mol Sci (2015) 0.75
Repression of Wnt/β-catenin response elements by p63 (TP63). Cell Cycle (2016) 0.75
Hepatocellular carcinoma: can circulating tumor cells and radiogenomics deliver personalized care? Am J Clin Oncol (2015) 0.75
Genetic and epigenetic alterations in hepatitis B virus-associated hepatocellular carcinoma. Virol Sin (2015) 0.75
Serine peptidase inhibitor Kazal type 1 (SPINK1) as novel downstream effector of the cadherin-17/β-catenin axis in hepatocellular carcinoma. Cell Oncol (Dordr) (2017) 0.75
Bioinformatics analysis of key genes and pathways for hepatocellular carcinoma transformed from cirrhosis. Medicine (Baltimore) (2017) 0.75
Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics (2009) 190.94
Global cancer statistics. CA Cancer J Clin (2011) 185.92
DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol (2003) 84.79
Integrative genomics viewer. Nat Biotechnol (2011) 42.83
SOAP2: an improved ultrafast tool for short read alignment. Bioinformatics (2009) 39.47
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
A census of human cancer genes. Nat Rev Cancer (2004) 36.20
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res (2010) 25.55
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
More powerful procedures for multiple significance testing. Stat Med (1990) 17.12
The global health burden of infection-associated cancers in the year 2002. Int J Cancer (2006) 13.57
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature (2011) 13.30
ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 13.07
High-resolution mapping of copy-number alterations with massively parallel sequencing. Nat Methods (2008) 12.56
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet (2010) 9.72
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet (2010) 8.41
Wnt signalling and its impact on development and cancer. Nat Rev Cancer (2008) 8.37
Molecular signatures database (MSigDB) 3.0. Bioinformatics (2011) 8.08
Secreted antagonists of the Wnt signalling pathway. J Cell Sci (2003) 8.02
Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling. Nature (2011) 6.09
Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet (2011) 5.68
Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet (2011) 5.67
Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature (2008) 5.38
AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet (2000) 5.26
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res (2009) 5.20
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet (2011) 4.38
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood (2010) 4.33
NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res (2010) 4.10
Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet (2012) 4.07
The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene (2010) 4.00
High-resolution characterization of a hepatocellular carcinoma genome. Nat Genet (2011) 3.86
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
Cancer genomics: from discovery science to personalized medicine. Nat Med (2011) 3.66
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat (2011) 3.63
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med (2008) 3.24
Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell (2011) 2.56
Identifying cancer driver genes in tumor genome sequencing studies. Bioinformatics (2010) 2.52
Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res (1998) 2.42
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov (2011) 2.38
Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol (2010) 2.28
Liver stem cells and hepatocellular carcinoma. Hepatology (2009) 2.27
Molecular basis of human Usher syndrome: deciphering the meshes of the Usher protein network provides insights into the pathomechanisms of the Usher disease. Exp Eye Res (2006) 2.19
The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem (2002) 2.14
A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4. Proc Natl Acad Sci U S A (2009) 2.06
Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med (2011) 2.03
Cancer gene discovery in hepatocellular carcinoma. J Hepatol (2010) 1.68
Geographic variation of p53 mutational profile in nonmalignant human liver. Science (1994) 1.51
HDPR1, a novel inhibitor of the WNT/beta-catenin signaling, is frequently downregulated in hepatocellular carcinoma: involvement of methylation-mediated gene silencing. Oncogene (2005) 1.34
Predictive genes in adjacent normal tissue are preferentially altered by sCNV during tumorigenesis in liver cancer and may rate limiting. PLoS One (2011) 1.26
Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J Mol Biol (2009) 1.26
GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J Hepatol (2011) 1.25
Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. Leukemia (2011) 1.18
Identification of genomic indels and structural variations using split reads. BMC Genomics (2011) 1.15
Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors. Haematologica (2011) 1.12
The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy. Cancer Lett (2009) 1.09
Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers. J Biol Chem (2009) 1.07
Next generation sequencing reveals genetic landscape of hepatocellular carcinomas. Cancer Lett (2012) 1.05
Focal adhesion kinase (FAK) gene amplification and its clinical implications in gastric cancer. Hum Pathol (2010) 1.03
Clinical significance of high focal adhesion kinase gene copy number and overexpression in invasive breast cancer. Breast Cancer Res Treat (2010) 0.98
Ruxolitinib. Nat Rev Drug Discov (2012) 0.96
Dickkopfs and Wnt/β-catenin signalling in liver cancer. World J Clin Oncol (2011) 0.94
High prevalence of K-ras-2 mutations in hepatocellular carcinomas in workers exposed to vinyl chloride. Int Arch Occup Environ Health (2001) 0.92
Mutational analysis of JAK1 gene in human hepatocellular carcinoma. Neoplasma (2009) 0.88
DNA damage and polyploidization. Adv Exp Med Biol (2010) 0.84
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
SOAP: short oligonucleotide alignment program. Bioinformatics (2008) 68.13
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
The diploid genome sequence of an Asian individual. Nature (2008) 46.29
De novo assembly of human genomes with massively parallel short read sequencing. Genome Res (2009) 45.91
A human gut microbial gene catalogue established by metagenomic sequencing. Nature (2010) 43.63
A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science (2002) 42.78
SOAP2: an improved ultrafast tool for short read alignment. Bioinformatics (2009) 39.47
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
Enterotypes of the human gut microbiome. Nature (2011) 24.36
Genetics of gene expression surveyed in maize, mouse and man. Nature (2003) 22.17
SOAPdenovo2: an empirically improved memory-efficient short-read de novo assembler. Gigascience (2012) 20.89
Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res (2008) 20.59
Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci U S A (2002) 20.48
The genome sequence of the malaria mosquito Anopheles gambiae. Science (2002) 20.36
Evolution of genes and genomes on the Drosophila phylogeny. Nature (2007) 18.01
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27
Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol (2003) 16.63
SNP detection for massively parallel whole-genome resequencing. Genome Res (2009) 15.96
The sequence and de novo assembly of the giant panda genome. Nature (2009) 15.76
Functional impact of global rare copy number variation in autism spectrum disorders. Nature (2010) 14.66
Rare variants create synthetic genome-wide associations. PLoS Biol (2010) 14.43
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science (2011) 13.16
WEGO: a web tool for plotting GO annotations. Nucleic Acids Res (2006) 13.06
Mapping copy number variation by population-scale genome sequencing. Nature (2011) 12.55
Genotype, haplotype and copy-number variation in worldwide human populations. Nature (2008) 12.40
A systematic survey of loss-of-function variants in human protein-coding genes. Science (2012) 12.25
A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature (2012) 11.68
Sequencing of 50 human exomes reveals adaptation to high altitude. Science (2010) 11.27
Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A (2005) 10.85
Structure of the novel ternary hydrides Li4Tt2D (Tt=Si and Ge). Acta Crystallogr B (2007) 10.58
A comparison of whole-genome shotgun-derived mouse chromosome 16 and the human genome. Science (2002) 9.59
Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature (2009) 9.47
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med (2013) 9.44
TreeFam: a curated database of phylogenetic trees of animal gene families. Nucleic Acids Res (2006) 8.83
The genome of the mesopolyploid crop species Brassica rapa. Nat Genet (2011) 8.23
The genome of the cucumber, Cucumis sativus L. Nat Genet (2009) 8.19
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97
An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science (2012) 7.94
Genome sequence and analysis of the tuber crop potato. Nature (2011) 7.77
The Genomes of Oryza sativa: a history of duplications. PLoS Biol (2005) 7.67
Ancient human genome sequence of an extinct Palaeo-Eskimo. Nature (2010) 7.51
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med (2013) 7.48
A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res (2008) 7.45
Open-source genomic analysis of Shiga-toxin-producing E. coli O104:H4. N Engl J Med (2011) 7.11
Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet (2010) 7.08
Gene expression patterns in human liver cancers. Mol Biol Cell (2002) 6.93
Richness of human gut microbiome correlates with metabolic markers. Nature (2013) 6.93
Cell-free formation of RNA granules: low complexity sequence domains form dynamic fibers within hydrogels. Cell (2012) 6.83
The microRNA spectrum in 12 body fluids. Clin Chem (2010) 6.82
TreeFam: 2008 Update. Nucleic Acids Res (2007) 6.63
A draft sequence for the genome of the domesticated silkworm (Bombyx mori). Science (2004) 6.62
Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron (2007) 6.60
Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell (2008) 6.48
Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med (2009) 6.45
Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. Mol Cell Biol (2007) 6.43
Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods (2005) 6.23
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet (2011) 5.73
Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet (2011) 5.68
Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell (2012) 5.62
Analyses of pig genomes provide insight into porcine demography and evolution. Nature (2012) 5.58
Rapid synthesis of auxin via a new tryptophan-dependent pathway is required for shade avoidance in plants. Cell (2008) 5.55
Building the sequence map of the human pan-genome. Nat Biotechnol (2009) 5.53
Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science (2010) 5.50
Resequencing of 200 human exomes identifies an excess of low-frequency non-synonymous coding variants. Nat Genet (2010) 5.44
The oyster genome reveals stress adaptation and complexity of shell formation. Nature (2012) 5.30
A genetic variation map for chicken with 2.8 million single-nucleotide polymorphisms. Nature (2004) 5.24
Resequencing of 31 wild and cultivated soybean genomes identifies patterns of genetic diversity and selection. Nat Genet (2010) 5.20